Abstract

Objective: To report the long-term follow-up of the first living-donor lobar lung transplantation performed in Latin America.

Description: The patient was a 12-year-old boy with post-infectious obliterative bronchiolitis with end-stage pulmonary disease. He was on continuous oxygen support, presenting with dyspnea even during minimal activity. He underwent bilateral lobar lung transplantation with living donors. The procedure was performed with the left and right lower lobes of two different related donors. In the second side cardiopulmonary bypass was required. The transplant was uneventful, and the patient was extubated after 14 hours and discharged with 44 days, after resolution of infectious, immunological and drug-related complications. After 12 years of follow-up, he presents with adequate lung function and has resumed his habitual activities.

Comments: Living-donor lobar lung transplantation is a complex procedure feasible for the treatment of selected pediatric end-stage pulmonary disease. This particular population might benefit from this approach since the availability of pediatric donors is very scarce and the clinical course of pediatric advanced pulmonary disease may be unpredictable.


Introduction

Since 1983, when the Toronto Lung Transplant Group reported the first successful lung transplantation, several advances have consolidated this procedure as a treatment modality for patients with end-stage pulmonary disease. However, the increase in the waiting lists for a new organ was not accompanied by an increase in the number of available donors. One of the alternatives found by the group of University of Southern California led by Vaughn Starnes, directed at a population with difficulties in receiving organs from cadavers (children needing bilateral transplantation), was performing a transplant with lobes from living donors in 1992. Starnes’ achievement was followed by that of a group by Hiroshi Date, from Okayama University, which conducted a living-donor lobar transplantation in a patient with ciliary dyskinesia in 1998. Afterwards, following the pioneering example in lung transplantation with cadaveric
donors, our group performed the first living-donor lung transplantation in Latin America, whose report is the aim of the present paper.

**Case description**

The patient, a 12-year-old boy with advanced pulmonary disease due to obliterative bronchiolitis, was admitted for pre-lung transplant evaluation. On that occasion, he was dependent on oxygen, with a forced expired volume in 1 second (FEV₁) of 150 mL (12% of the predicted value) and a forced vital capacity (FVC) of 230 mL (17% of the predicted value). The 6-minute walk test was not performed due to lack of clinical conditions (Figure 1). There was no colonization of the lower airways. Two related donors were selected based on blood compatibility and lobe size. Donors underwent fibrobronchoscopy, evidencing anatomically normal lower airways.

Subsequently, the bilateral lung transplantation was conducted by sequential posterolateral thoracotomy. Orotracheal intubation was performed with Carlens’ tube, and blood pressure and pulmonary artery pressure were monitored invasively. Because perfusion scintigraphy showed homogeneous disease (right perfusion 49%), we chose to begin from the left side due to the fact that cannulation for cardiopulmonary bypass (CPB) was easier in the right side (the second side shows a higher risk of requirement for CPB). The first donor underwent left lower lobectomy, with lobe preparation on a special table with retrograde and antegrade perfusion with 4 L of Perfadex and ambient air manual ventilation. After the recipient underwent left pneumonectomy, the implantation went on with mouth to mouth bronchial anastomosis, with a continuous suture in the membranous wall and simple stitches of 4-0 polydioxanone in the cartilaginous wall, followed by arterial anastomosis with a continuous 5-0 polypropylene suture and venoatrial anastomosis with a continuous 4-0 polypropylene suture. The reperfusion was performed after 50 minutes of ischemia by slowly opening the pulmonary artery clamp and manually ventilating the lobe. A similar technique was performed in the right side, using the lower lobe of the second donor, with ischemia time of 55 minutes. However, in this side, CPB was required due to respiratory instability, with cannulation of the aorta and right atrium. CPB time was 54 minutes. Fibrobronchoscopy immediately after surgery showed permeable anastomoses with excellent appearance.

In the intensive care unit (ICU), he required vasoactive drugs (dopamine) for 18 hours and was extubated 14 hours after admission. The post-surgery period was marked by two episodes of acute rejection, the first of which (17 days after surgery) was treated with pulse therapy and the second (33 days after surgery) also with pulse therapy, together with a change in the immunosuppression scheme by replacing azathioprine with mycophenolate mofetil. Moreover, he presented with respiratory infection, with the isolation of *Stenotrophomonas maltophilia* in bronchial washing (12 days after surgery) and treatment with sulfamethoxazole-trimethoprim. Another post-surgery complication was neurotoxicity due to cyclosporine, with important symptoms compatible with peripheral neuropathy and prompt improvement after transient suspension of the drug. After 33 days he was discharged from the ICU and after 44 days was discharged from hospital in good general state and with no oxygen requirement.

![Figure 1](image1.png) - Chest radiograph before lobar transplantation showing signs of lung hyperinflation

![Figure 2](image2.png) - Progression of the percentage of forced expiratory volume in 1 second (FEV₁%) after transplantation
Transplantations were reported in 1992. Subsequently, in order to fill this important gap, the first living-donor lung of a pool of readily available donors was imperative. In unpredictable course, such as cystic fibrosis, the creation of a pool of readily available donors was imperative. Due to the difficulty in finding a suitable donor for this group and to the peculiarities of the Japanese population, which has a low incidence of cystic fibrosis and presents pulmonary arterial hypertension and interstitial fibrosis as the main indications for transplantation. As in our case, average ICU and hospital stay tend to be long (23 and 64 days respectively in their study).

In the series of Sweet et al., survival at 1 and 3 years was 60 and 48%, respectively. Despite a worse survival compared with cadaveric donor recipients (mostly due to infectious complications), evolution time with no obliterative bronchiolitis was significantly lower (92 vs. 75% at 1 year and 85 vs. 53% at 3 years). Corroborating this finding, our patient is free of obliterative bronchiolitis 12 years after transplantation.

In the largest series, with 138 cases (90 adults and 48 children), cystic fibrosis was the indication for transplantation in 86% of them. Survival at 1, 3 and 5 years were 70, 54 and 45%, respectively. In this study, the authors emphasized that 67% of the patients were hospitalized at the moment of transplant indication, and 20% depended on mechanical ventilation. Moreover, the cause of death in the first 30 days and in the first year was the same: infection (mainly by Pseudomonas sp., Staphylococcus sp., and Aspergillus sp.). After the first year, obliterative bronchiolitis joins infection as the main cause of death.

Another important issue concerns donor morbidity. It is known that lung lobectomy, even in healthy patients, is not free of risks. In an assessment of 253 donors, Bowdish et al. found 19.8% of morbidity and no deaths. In a recent publication, our group reported complications in 32 donors, with 31.25% of morbidity and zero mortality. Again, it was emphasized the crucial need of balancing the risks of the procedure (for the three patients) with its potential benefits. Other very important data to be considered at the moment of indication for living-donor transplantation are the current course of the pneumopathy and the real chance of finding a compatible cadaveric donor, in case the patient is included in the waiting list.

In summary, we highlight the importance of considering living-donor lung transplantation in well selected cases. This transplant modality may represent the only alternative in pediatric patients with end-stage pneumopathies. The results are encouraging when considering the severity of the study population. Additionally, it is possible to obtain long-term survival with quality of life.
References


Correspondence:
Luzielio Alves Sidney Filho
Rua Dr. Jair de Andrade, 750/104, Itapuã
CEP 29101-700 - Vila Velha, ES - Brazil
Tel.: +55 (27) 8145.4140
E-mail: luzieliofilho@gmail.com